idorsia reaching out for more
play

Idorsia Reaching out for more Idorsia - Investor Webcast - 24 October 2017 The following information contains certain forward-looking statements, relating to the companys business, which can be identified by the use of

0 downloads 4 Views 627 KB Size Report
  1. Idorsia – Reaching out for more Idorsia - Investor Webcast - 24 October 2017

  2. The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. 2 Idorsia - Investor Webcast | October 2017

  3. We are off to an excellent start Jean-Paul Clozel, CEO

  4. A new venture 1 Innovative deal with J & J is the basis for good start 2 Excellent collaboration with Actelion / J & J 3 Fully functional since day 1 4 Establishing strong foundation for successful future 4 Idorsia - Investor Webcast | October 2017

  5. Idorsia’s strengths The crucial elements for bringing R&D to successful medicines An experienced A full team of research and State-of-the-art CHF 1 billion highly development facilities in cash qualified pipeline professionals 5 Idorsia - Investor Webcast | October 2017

  6. Idorsia’s Clinical Development Pipeline Status Compound Mechanism of Action Target indications Aprocitentan* Endothelin receptor antagonist Resistant hypertension ACT-541468 Dual orexin receptor antagonist Insomnia Phase 2 Cenerimod S1P 1 receptor modulator Systemic lupus erythematosus Clazosentan** Endothelin receptor antagonist Vasospasm associated with aneurysmal subarachnoid hemorrhage Vamorolone*** Non-hormonal steroid modulator Duchenne muscular dystrophy Phase 1b Lucerastat Glucosylceramide synthase inhibitor Fabry disease ACT-246475 P2Y12 receptor antagonist Acute coronary syndrome ACT-774312 CRTH2 receptor antagonist Asthma & allergy disorders Phase 1 ACT-539313 Selective orexin 1 receptor antagonist Anxiety ACT-709478 T-type calcium channel blocker Epilepsy *Johnson and Johnson has option to jointly develop and solely commercialize Aprocitentan worldwide **In Japan a Phase 2 study was completed in 2017 and market registration trials have started ***Idorsia has exclusive option to worldwide rights to ReveraGen’s Vamorolone 6 Idorsia - Investor Webcast | October 2017

  7. Aprocitentan Results from study of oral, potent, once-a-day drug for control of blood pressure • The effect of aprocitentan observed is clinically relevant • The effect of aprocitentan covers the 24 h period • Aprocitentan was well tolerated across all four doses in this patient population • The overall frequency of adverse events was similar on aprocitentan to placebo • It is anticipated that the results can be extrapolated to resistant hypertension • The study provides the necessary information for moving into pivotal registration program Aprocitentan is investigational, in development and not approved or marketed in any country. 7 Idorsia - Investor Webcast | October 2017

  8. ACT-541468 (DORA) Novel dual orexin receptor antagonist for treatment of insomnia Phase 2 program overview: • Two dose-response studies to evaluate the safety and efficacy of DORA in adult and elderly patients with insomnia • Adult study with zolpidem as an active reference − Study 1: 360 adult insomnia patients − Study 2: 58 elderly insomnia patients ACT-541468 is investigational, in development and not approved or marketed in any country. 8 Idorsia - Investor Webcast | October 2017

  9. ACT-541468 (DORA) • Idorsia has significant expertise in the discovery and development of DORAs • DORAs have the potential to promote sleep and maintain a natural sleep architecture • PK/PD profile of ACT-541468 suggests an optimal combination of effect on the CNS and low residual concentration next-day • Both Phase 2 studies, in adult and elderly patients, meet their primary endpoints • Results show desired effect on sleep maintenance and onset – significant dose-response relationship • Idorsia to advance ACT-541468 into pivotal registration program ACT-541468 is investigational, in development and not approved or marketed in any country. 9 Idorsia - Investor Webcast | October 2017

  10. Idorsia’s Clinical Development Pipeline Status Compound Mechanism of Action Target indications Aprocitentan* Endothelin receptor antagonist Resistant hypertension ACT-541468 Dual orexin receptor antagonist Insomnia Phase 2 Cenerimod S1P 1 receptor modulator Systemic lupus erythematosus Clazosentan** Endothelin receptor antagonist Vasospasm associated with aneurysmal subarachnoid hemorrhage Vamorolone*** Non-hormonal steroid modulator Duchenne muscular dystrophy Phase 1b Lucerastat Glucosylceramide synthase inhibitor Fabry disease ACT-246475 P2Y12 receptor antagonist Acute coronary syndrome ACT-774312 CRTH2 receptor antagonist Asthma & allergy disorders Phase 1 ACT-539313 Selective orexin 1 receptor antagonist Anxiety ACT-709478 T-type calcium channel blocker Epilepsy *Johnson and Johnson has option to jointly develop and solely commercialize Aprocitentan worldwide **In Japan a Phase 2 study was completed in 2017 and market registration trials have started ***Idorsia has exclusive option to worldwide rights to ReveraGen’s Vamorolone 10 Idorsia - Investor Webcast | October 2017

  11. Financial Update André Muller, CFO

  12. Operating results Financial results as of 30 September 2017 Non-GAAP US-GAAP -34 -71 -79 -23 -14 -5 -3 Revenues Research Development G&A Non-GAAP D&A SBC US-GAAP Operating Operating results results 12 Idorsia - Investor Webcast | October 2017

  13. Net results Financial results as of 30 September 2017 Non-GAAP US-GAAP -71 -73 -2 +1 -79 -4 -82 Operating results Financial Income Tax Non-Controlling Interests Net results results results 13 Idorsia - Investor Webcast | October 2017

  14. Cash flow Financial results as of 30 September 2017 +22 +2 - 72 1,000 952 Cash at Funds from Working Capital Capex / Liquidity as of Demerger Operations Requirements Other 30 Sep 2017 14 Idorsia - Investor Webcast | October 2017

  15. Liquidity Financial results as of 30 September 2017 952 250 Cash deposits > 3 months Cash deposits 150 < 3 months 1,000 Cash and Cash Equivalents 552 Liquidity at Liquidity as of demerger 30 Sep 2017 15 Idorsia - Investor Webcast | October 2017

  16. Convertible bond Financial results as of 30 September 2017 580 445 135 Equity component 82 Debt component 363 445 Convertible Bond Convertible Bond at demerger as of 30 Sep 2017 16 Idorsia - Investor Webcast | October 2017

  17. Potential issued shares Financial results as of 30 September 2017 Issued common shares = 119.1 million Potential issued shares = 162.7 million 162.7 157.8 4.9 38.7 Equity instruments 50.5 Equity derivatives 119.1 Issued common 107.3 shares Potential shares Potential shares at demerger as of 30 Sep 2017 17 Idorsia - Investor Webcast | October 2017

  18. Financial Guidance for 2017 As of 24 October 2017 Non-GAAP Operating Expenses = -10 • CHF -160 / -170 million -61 2017 = 6 ½ months activity since • demerger from Actelion -89 -99 -160 -170 Q2 2017 Q3 2017 Q4 2017 FY 2017 (Actual) (Actual) (Estimate) (Estimate) 18 Idorsia - Investor Webcast | October 2017

  19. Execution becomes the strategy 19 Idorsia - Investor Webcast | October 2017

Recommend Documents


idorsia reaching out for more
Idorsia Reaching out for more

Idorsia Reaching out for more Idorsia - Investor Webcast - 6 February 2018

reaching out on missions reaching out on missions
REACHING OUT On Missions REACHING OUT

REACHING OUT On Missions REACHING OUT On Missions Agenda 1. Overview on

reaching for
reaching for policy and practice for

Southwest Michigan Sustainable Business Forum and U.S. Green Building Council

reaching a culture reaching a culture that has that has
REACHING A CULTURE REACHING A CULTURE

REACHING A CULTURE REACHING A CULTURE THAT HAS THAT HAS ABANDONED SCRIPTURE

lecture 7
LECTURE 7: when they are self

Reaching Agreements How do agents reaching agreements LECTURE 7: when they

reaching definitions
Reaching Definitions Global Opt:

Reaching Definitions Global Opt: Reaching Definitions Concept of definition

reaching as many viewers as possible using only libre
Reaching as many viewers as possible

How Libre can you go? Reaching as many viewers as possible using only libre

transforming nyrstar port pirie
Transforming Nyrstar Port Pirie:

16 MAY 2014 Change pictures to MP Nyrstar proceeds with Port Pirie

reaching the unreached who cannot read
Reaching the unreached who cannot read

Reaching the unreached who cannot read By Johan Grobler

students teaching and reaching students
Students Teaching and Reaching

Students Teaching and Reaching Students STARS Club The Students Teaching and

inspire medical systems inc
Inspire Medical Systems, Inc. s

Inspire Medical Systems, Inc. s Company Presentation September 2018 NYSE:

better safe
BETTER SAFE WELCOAS ONLINE BULLETIN

H E A LT H B U L L E T I N S BETTER SAFE WELCOAS ONLINE BULLETIN FOR YOUR FA

cdc public health grand rounds
CDC PUBLIC HEALTH GRAND ROUNDS Chronic

CDC PUBLIC HEALTH GRAND ROUNDS Chronic Fatigue Syndrome: A Advancing

spectrum disorder asd
Spectrum Disorder (ASD) Luci Wiggs

Sleep disturbance in children with Autism Spectrum Disorder (ASD) Luci Wiggs

seafarer sleepiness and fatigue why are they a problem
Seafarer Sleepiness and Fatigue Why

Click to edit Master title style Seafarer Sleepiness and Fatigue Why are they

adolescent sleep
Adolescent Sleep Daniel S. Lewin,

Adolescent Sleep Daniel S. Lewin, Ph.D., D,ABSM Associate Director, Pediatric

board of governors meeting
Board of Governors Meeting via

Board of Governors Meeting via Teleconference/Webinar May 23, 2016 10:00

corporate presentation
Corporate Presentation June 2020

Corporate Presentation June 2020 Abeona Therapeutics Corporate Presentation,

new research in me cfs
NEW RESEARCH IN ME/CFS INVEST IN ME

NEW RESEARCH IN ME/CFS INVEST IN ME SPRING 2017 MAJOR CATEGORIES 1.

provider
PROVIDER Senior Director of STI

Mary Foote, MD, MPH Senior Health Security Specialist, Bureau of Healthcare

harnessing the power of the innate immune system
HARNESSING THE POWER OF THE INNATE

HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune

harnessing the power of the innate immune system
HARNESSING THE POWER OF THE INNATE

HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune